Примери за използване на Case of concomitant на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Caution is advised in case of concomitant treatment with CYP3A4 inhibitor.
As at a higher dose of mirtazapine a more pronounced effect can not be excluded,it is advisable to monitor the INR in case of concomitant treatment of warfarin with mirtazapine.
In case of concomitant heart disease need to follow a policy of therapy adrenostimulyatorov?;
Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes,especially in case of concomitant treatment susceptible to induce bleeding.
In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage.
Renal function should also be assessed when a change in renal function is suspected during treatment(e.g. hypovolaemia,dehydration, and in case of concomitant use of certain medicinal products).
In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage.
Topical steroids or low doses of systemic corticosteroids may be used during treatment with mogamulizumab; however,the risk of serious infection and/or viral reactivation may be higher in case of concomitant administration with systemic immunosuppressive agents.
In the case of concomitant use with warfarin or other indirect anticoagulants, prothrombin time should be monitored.
Rise in serum calcium concentration is to be anticipated in case of concomitant administration of hydrochlorothiazide; therefore close monitoring of serum calcium is required.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.
Caution is recommended in case of concomitant use with sensitive CYP3A4 substrates with a narrow therapeutic index(see section 4.4).
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.
In the case of concomitant administration of these products, prothrombin time(PT) or other suitable coagulation tests should be monitored.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant therapy with other topical ocular medicinal products, an interval of ten minutes should be allowed between successive applications.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
In case of concomitant therapy with other topical ocular medicines, an interval of five to ten minutes should be allowed between successive applications.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.
In case of concomitant antiviral therapy for hepatitis C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.
In the case of concomitant administration of these products, prothrombin time(PT) or other suitable coagulation tests should be monitored.
In the case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.